Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

NeuShen Raises $20 Million in Pre-A Round for CNS Gene Therapy/Small Molecule Drugs

publication date: Sep 29, 2022

NeuShen Therapeutics, a Shanghai-Boston CNS startup, closed a $20 million Pre-A financing to advance its AAV-based gene therapy and small molecule discovery platforms. The company was founded by Joan Shen, MD, PhD, who previously was CEO at Shanghai’s I-Mab. NeuShen is currently in discussions with the Horae Gene Therapy Center, UMass Chan Medical School to develop several of the Center’s CNS gene therapy projects. The company said it would use the capital to add team members and advance in-house CNS drug discovery in the US and China. The financing was led by Lapam, a China VC. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital